ClinicalTrials.gg
CompletedNCT05148312BORAUpdated Nov 3, 2022

Single-dose AQ001S PK Study in Healthy Volunteers

A Phase 1 interventional study of Budesonide Inhalant Product in Pharmacokinetics, sponsored by Aquilon Pharmaceuticals S.A.. Completed at 1 site in Bulgaria. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-03.

Sponsored by Aquilon Pharmaceuticals S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a randomized, open label, single-center, single-dose, four-period crossover clinical study to assess the pharmacokinetic profile and safety of a budesonide inhalation solution (AQ001S) compared to a budesonide inhalation suspension (comparator) in healthy volunteers.

Read the detailed description

This is a randomized, open label, single-center, single-dose, four-period crossover clinical study to assess the pharmacokinetic profile and safety of a budesonide inhalation solution (AQ001S) compared to a budesonide inhalation suspension (comparator) in healthy volunteers. Three (3) different AQ001S concentrations (i.e. 0.125 mg/2 mL, 0.250 mg/2mL and 0.500 mg/2 mL) will be compared to budesonide inhalation suspension 1.0 mg/2 ml.

Twenty (20) male and female healthy volunteers, from 18 to 60 years old, must complete the study. The study drug will be administered by nebulization.

The primary PK objective is to characterize the pharmacokinetic (PK) profile of AQ001S inhalation solution.

The primary safety objective is to assess the safety of AQ001S inhalation solution.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Aquilon Pharmaceuticals S.A. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have given written .
  2. Healthy volunteers of both genders, aged ≥ 18 and ≤ 60 years.
  3. Subjects with body weight > 45 kg and ≥ 18.5 and ≤ 24.9kg/m2.
  4. Healthy volunteers are declared healthy based on medical history, physical examination, , pulmonary function test ( ≥ 80% of the predicted normal value and Forced Expiratory Volume in 1 second/ Forced Vital Capacity ≥ 70%).
  5. Clinical laboratory values within the laboratory stated normal range; if not within this range, they must be without any clinical significance according to the Investigator.
  6. Subjects who never smoked.
  7. Women of (WOCBP) may be enrolled if they practice a method of with a reliability of at least 90% and agree to continue doing so throughout the treatment period (e.g. condom, intrauterine device or hormonal contraception).
  8. Any female subject with childbearing potential has a negative pregnancy test at Screening visit and prior to dosing at each treatment period.
  9. Reliable subjects who are willing to be available for the duration of the clinical study and willing to comply with clinical study procedures.
  10. Subjects who have the ability to understand the requirements of the clinical study.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormality identified at the screening medical assessment (physical examination/medical history) or clinically relevant laboratory abnormalities.
  2. Clinically significant history or presence of pulmonary malformations, chronic bronchitis, asthma, emphysema, cystic fibrosis or any other pulmonary disease
  3. History or presence of pulmonary tuberculosis.
  4. Viral or bacterial upper or lower respiratory tract infection, or sinus or middle ear infection, within 4 weeks prior to the screening visit.
  5. Untreated oral candidiasis.
  6. History or presence of prolonged (> 450 ms), or any other clinically significant abnormalities as judged by the Investigator based on 12-lead electrocardiogram recordings at Screening Visit.
  7. History or presence of of any system organ class (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years prior to Screening Visit, regardless of whether there is no evidence of local recurrence or .
  8. Eye disorders, especially glaucoma, or a family history of glaucoma.
  9. History of alcohol or drug abuse.
  10. Inability to abstain from alcohol consumption for the duration of study period.
  11. treatment, including topical and systemic (e.g., oral, parenteral, ocular, nasal or inhaled), within 4 weeks before Screening Visit.
  12. Use of prescription or non-prescription drugs, except for simple analgesics (e.g. paracetamol) and hormonal for women, including vitamins, herbal and dietary supplements (including St John's Wort [Hypericum]) within 7 days (or 2 weeks if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the Screening Visit.
  13. Pregnant or breastfeeding female subjects.
  14. History of or existing to budesonide or any other study medication ingredients.
  15. Blood or plasma donation within 4 weeks prior to Screening Visit.
  16. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the clinical study.
  17. History or presence of any other clinically relevant disease of any major system organ class (e.g. cardiovascular, pulmonary, renal, hepatic, gastrointestinal, reproductive, endocrinological including any type of Diabetes mellitus, neurological, psychiatric or orthopedic disease) as judged by the Investigator.
  18. COVID-19, and C and positive tests
  19. Any COVID-19 vaccine within 2 weeks prior to the first dose of study drugs, and during the entire study participation including 2 weeks after the last dose of study drug.
  20. Subjects who participated in an study within the 12 weeks prior to the start of the study
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    AQ001S 0.125 mg/2mL single-dose

    AQ001S 0.125 mg/2 ml (budesonide 0.125 mg/2 ml inhalation solution) single-dose administered by nebulization.

    Drug: Budesonide Inhalant Product

  • Experimental
    AQ001S 0.250 mg/2mL single-dose

    AQ001S 0.250 mg/2 ml (budesonide 0.250 mg/2 ml inhalation solution) single-dose administered by nebulization.

    Drug: Budesonide Inhalant Product

  • Experimental
    AQ001S 0.500 mg/2mL single-dose

    AQ001S 0.500 mg/2 ml (budesonide 0.500 mg/2 ml inhalation solution) single-dose administered by nebulization.

    Drug: Budesonide Inhalant Product

  • Active comparator
    Budesonide inhalation suspension 1.0 mg/2 ml single-dose

    Pulmicort Respules® 1.0 mg/2 ml is a budesonide inhalation suspension administered by nebulization.

    Drug: Budesonide Inhalant Product

Interventions

  • Single-dose of budesonide solution administered by nebulization.

    Also known as: Budesonide solution administered by nebulization

06

What researchers measure

Primary outcomes

  1. Assessment of pharmacokinetics (Cmax) of budesonide through analysis of blood samples

    Blood samples will be collected from each subject using an indwelling intravenous catheter. In total 17 blood samples for PK assessments over 24 hours will be collected.

    Time frame: Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose

  2. Assessment of pharmacokinetics (Tmax) of budesonide through analysis of blood samples

    Blood samples will be collected from each subject using an indwelling intravenous catheter. In total 17 blood samples for PK assessments over 24 hours will be collected.

    Time frame: Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose

  3. Assessment of pharmacokinetics (AUC) of budesonide through analysis of blood samples

    Blood samples will be collected from each subject using an indwelling intravenous catheter. In total 17 blood samples for PK assessments over 24 hours will be collected.

    Time frame: Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose

  4. Assessment of the safety through to incidence of Adverse Events of AQ001S inhalation solution

    Incidence of treatment-related adverse events (AE), including acute bronchospasm

    Time frame: From baseline up to 17 days after first study drug intake

  5. Assessment of the general tolerability through to vital signs (blood pressure: systolic and diastolic blood pressure) of AQ001S inhalation solution

    Vital signs assessment through blood pressure (systolic and diastolic blood pressure)

    Time frame: From baseline up to 17 days after first study drug intake

  6. Assessment of the general tolerability through to vital signs (pulse rate) of AQ001S inhalation solution

    Vital signs assessment through pulse rate

    Time frame: From baseline up to 17 days after first study drug intake

  7. Assessment of the general tolerability through to vital signs (respiratory rate) of AQ001S inhalation solution

    Vital signs assessment through respiratory rate

    Time frame: From baseline up to 17 days after first study drug intake

  8. Assessment of the general tolerability through to ECG (PR interval duration)

    ECG assessment through to PR interval duration

    Time frame: From baseline up to 17 days after first study drug intake

  9. Assessment of the general tolerability through to ECG (heart rhythm) of AQ001S inhalation solution

    ECG assessment through to heart rhythm

    Time frame: From baseline up to 17 days after first study drug intake

  10. Assessment of the general tolerability through to ECG (QRS interval duration) of AQ001S inhalation solution

    ECG assessment through to QRS interval duration

    Time frame: From baseline up to 17 days after first study drug intake

  11. Assessment of the general tolerability through to ECG (Corrected QT interval (QTc)) of AQ001S inhalation solution

    ECG assessment through to Corrected QT interval

    Time frame: From baseline up to 17 days after first study drug intake

  12. Assessment of the general tolerability through to ECG (QT interval duration) of AQ001S inhalation solution

    ECG assessment through to QT interval duration

    Time frame: From baseline up to 17 days after first study drug intake

  13. Assessment of the general tolerability through to physical examination

    General tolerability through the rate of patients with observed abnormalities in the following organic systems: general appearance, head and neck (incl. oropharyngeal examination), skin, respiratory system, cardiovascular system, abdomen, urogenital system, nervous system, ear, eyes and nose, musculoskeletal system

    Time frame: From baseline up to 17 days after first study drug intake

  14. Assessment of the local tolerability through to increased bronchial irritability of AQ001S inhalation solution

    Incidence of Increased bronchial irritability

    Time frame: From baseline up to 17 days after first study drug intake

  15. Assessment of the local tolerability through to paradoxical bronchospasm of AQ001S inhalation solution

    Incidence of paradoxical bronchospasm

    Time frame: From baseline up to 17 days after first study drug intake

  16. Assessment of the local tolerability through to oropharyngeal examination ((e.g. vocal cord myopathy, fungal infection) of AQ001S inhalation solution

    Incidence of oropharyngeal examination ((e.g. vocal cord myopathy, fungal infection)

    Time frame: From baseline up to 17 days after first study drug intake

07

Study locations

1 site
  • MC Comac Medical Ltd.
    Sofia, 1612, Bulgaria
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Clinical study report

Time frame: Beginning 6 months and ending 5 years following article publication.

Access criteria: To Investigators whose proposed use of the data has been approved by sponsor.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Dec 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2021
First posted
Dec 8, 2021
StartActual
Nov 12, 2021
Primary completionActual
Dec 24, 2021
CompletionActual
Feb 21, 2022
Last update
Nov 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05148312
Lead sponsor
Aquilon Pharmaceuticals S.A.
Responsible party
Sponsor
First posted
Dec 8, 2021
Start date
Nov 12, 2021
Primary completion
Dec 24, 2021
Completion
Feb 21, 2022
Last update
Nov 3, 2022

Study contacts

Dobrin Svinarov, MD
principal investigator · MC Comac Medical Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion